

Details of Q1 FY23 Investor Webinar

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") will release its Q1 FY23 Quarterly Activities Report & Appendix 4C on Thursday, 27 October 2022 pre-market.

An investor webinar will be held to discuss the Q1 FY23 results. Please find the details below:

Presenting: Microba CEO, Dr Luke Reid

Time: 10:30 am AEDT (9:30 AEST) on Monday, 31 October 2022

To register for the session and for more information on the conference click below. Investors can submit questions prior to the webinar to simon@nwrcommunications.com.au or do so via the Q&A functions on Zoom.

https://us02web.zoom.us/webinar/register/WN_B0_RqfbzQdm6yMp4OEV2AQ

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

Simon Hinsley

Investor / Media Relations

E: simon@nwrcommunications.com.au

T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.